Press Releases

1 Epidemiological study on Oropharyngeal Candidiasis and results on miconazole MBT* compliance were presented at the 51st ASTRO Annual Meeting

Results on epidemiologic study on Oropharyngeal Candidiasis (OPC) in oncology were presented at the 51st ASTRO (American Society for Therapeutic Radiology and Oncology) Meeting in Chicago (From November 1st to November 5th). Pr David Azria (Anticancer Center Montpellier) has presented the data collected in 35 public and private oncology centers. This study of 2027 cancer patients revealed a 10% prevalence…read more →

BioAlliance Pharma presents additional US pivotal Phase III results on Loramyc™ (miconazole Lauriad®) at the 47th Annual Meeting of the IDSA

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st). The additional results from BioAlliance Pharma’s pivotal Phase III study with miconazole Lauriad®…read more →

Q3 2009: Strong Sales Growth and Significant Progress in Clinical Development

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a consolidated turnover of €1.6 million for the third quarter of 2009. Turnover and cash reserves Quarterly sales of Loramyc® in France remained strong over the summer, totaling €0.5 million – more than twice the figure for…read more →

Two new appointments to BioAlliance Pharma’s Supervisory Board in phase with the company’s development

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members. The Supervisory Board has co-opted André Ulmann MD, PhD (founder and CEO of HRA Pharma since 1996) and the company ING Belgium (represented by Denis Biju-Duval, BEng, MBA, Head of…read more →

BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad® and the submission of a Clonidine Lauriad® Phase II clinical trial application

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®. This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers. It is expected to…read more →

BioAlliance Pharma announces that the civil action filed by Eurofins in the United States is rejected

BioAlliance Pharma SA (Euronext Paris – BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal. In 2008, Eurofins Pharma US Holding Inc. and one of its affiliates Viralliance Inc (“Eurofins”) had filed a civil…read more →

BioAlliance Pharma makes four presentations at the 49th ICAAC meeting

including three phase III study results with miconazole Lauriad® and one with its integrase inhibitor BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad® and anti-integrase inhibitor. The results of a phase III study with miconazole Lauriad® mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to…read more →

BioAlliance Pharma to present at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine

(Bergen, Norway, August 31 to September 2, 2009) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter’s advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to…read more →

BioAlliance Pharma announces positive preliminary pivotal phase III results in herpes labialis with acyclovir Lauriad®

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg…read more →

Consolidated accounts for the first half of 2009

• Loramyc® sales triple • submission of a marketing authorization application for Setofilm® in Europe • submission of a new drug application for Loramyc® in the USA • significant progress in the supportive care portfolio • OSEO funding validates the company’s innovations BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer…read more →

Loramyc® obtains Marketing Authorization in Switzerland

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that Loramyc® has obtained Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromised patients (mainly cancer and AIDS patients with oral opportunistic infections). “This approval represents an important milestone for Loramyc® which is now…read more →

FDA Accepts Drug Application for Miconazole Lauriad® (Loramyc®) to Treat Oropharyngeal Candidiasis

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive…read more →

BioAlliance Pharma submits clinical trial new drug application

and announces results of its July 27th 2009 General Assembly Meeting BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des…read more →

Turnover for Q2 2009

sustained sales growth and an NDA for Loramyc® in the USA BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it had generated a consolidated turnover of €1.5 million during the second quarter of 2009. Turnover Quarterly sales of Loramyc® in France continued to grow…read more →

BioAlliance Pharma signs a co-promotion agreement with Lundbeck for in-hospital prescription of the antidepressant Seroplex®

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the signature of a 2009 co-promotion agreement with Lundbeck for the latter’s Seroplex® antidepressant. BioAlliance Pharma will co-promote Seroplex® to its core healthcare partners (notably oncologists, radiotherapists and hematologists) as part of a comprehensive approach to patient…read more →